• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 25, 2019 at 07:22: PM
via AbbVie (NYSE: ABBV) raised concerns among investors the last time it delivered quarterly results. The drugmaker's January report showed it had missed analysts' estimates on both the top and bottom lines in the fourth quarter, after getting surprised somewhat by its rivals' aggressive pricing of biosimilars to its top-selling treatment, Humira, in Europe.

article source
 

<



Similar threads

cafead
5 Things You Need to Know From AbbVie&#039;s Q2 Earnings Results
Replies
0
Views
172
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Forget Humira -- Here&#039;s What You Need to Know About AbbVie
Replies
0
Views
146
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie &amp; Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Replies
0
Views
125
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
MDMA therapy is facing an imminent FDA decision. Here’s what you need to know
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Unpacking the PREVAIL Act: What pharma marketers need to know
Replies
0
Views
14
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote